Table 2.
Comparing AOM vs placebo with SGA-LAIsa vs placebo
| AOM vs placebo | SGA-LAIsa vs placebo | |
|---|---|---|
| PANSS total scores | SMD =0.65, 95% CI =0.41–0.90 | SMD =0.34, 95% CI =0.25–0.43 |
| Responder rate | RR =0.33, 95% CI =0.23–0.48, NNT =4 | RR =0.54, 95% CI =0.45–0.66, NNT =6 |
| Discontinuation due to all causes | RR =0.54, 95% CI =0.41–0.71, NNH =4 | RR =0.69, 95% CI =0.58–0.83, NNH =25 |
| Death | RR =0.50, 95% CI =0.05–4.77 | RR =0.33, 95% CI =0.06–1.89 |
| All treatment-emergent adverse events | RR =1.05, 95% CI =0.98–1.13 | RR =1.02, 95% CI =0.95–1.08 |
| Insomnia | RR =0.95, 95% CI =0.63–1.44 | RR =0.80, 95% CI =0.64–1.01 |
| Anxiety | RR =0.87, 95% CI =0.51–1.47 | RR =0.67, 95% CI =0.48–0.94, NNH =35 |
| Extrapyramidal symptom | RR =1.63, 95% CI =0.64–4.15 | RR =2.04, 95% CI =1.15–3.61, NNH =10 |
| Anticholinergic use | RR =1.50, 95% CI =1.04–2.18, NNH =17 | RR =1.51, 95% CI =1.13–2.02, NNH =20 |
| Weight gain | RR =1.58, 95% CI =0.92–2.73 | RR =2.75, 95% CI =1.87–4.03, NNH =16 |
| Injection site pain | RR =3.62, 95% CI =0.50–26.31 | RR =1.14, 95% CI =0.96–1.36 |
Note: Reproduced from Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of ran-domized-controlled trials. Int Clin Psychopharmacol. 2013;28(2):57–66.8
a
SGA-LAIs included risperidone-LAI, paliperidone-LAI, and olanzapine-LAI.
Abbreviations: AOM, aripiprazole once monthly; CI, confidence interval; LAI, long acting injectables; NNH (T), number needed to harm (treat); PANSS, Positive and Negative Syndrome Scale; RR, relative risk; SD, standard deviation; SGA, second generation antipsychotic; SMD, standardized mean difference.